KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT (2017 - 2025)

Historic EBT for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$5.2 million.

  • Amneal Pharmaceuticals' EBT fell 13386.5% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 15574.68%. This contributed to the annual value of -$55.0 million for FY2024, which is 3661.04% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its EBT stood at -$5.2 million for Q3 2025, which was down 13386.5% from $51.7 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' EBT's 5-year high stood at $51.7 million during Q2 2025, with a 5-year trough of -$232.7 million in Q2 2022.
  • In the last 5 years, Amneal Pharmaceuticals' EBT had a median value of -$2.0 million in 2021 and averaged -$12.0 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' EBT in the last 5 years was 95307.34% (2023), contrasted with its biggest fall of 99028.09% (2023).
  • Over the past 5 years, Amneal Pharmaceuticals' EBT (Quarter) stood at -$16.3 million in 2021, then soared by 53.09% to -$7.7 million in 2022, then plummeted by 990.28% to -$83.5 million in 2023, then surged by 81.65% to -$15.3 million in 2024, then skyrocketed by 65.91% to -$5.2 million in 2025.
  • Its EBT stands at -$5.2 million for Q3 2025, versus $51.7 million for Q2 2025 and $37.5 million for Q1 2025.